These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7489345)

  • 21. Interferon alpha therapy in patients with chronic type C hepatitis: changes of serum ALT, anti-HCV & HCV-RNA.
    Cho HJ; Dong SH; Lee MS; Kim HY; Park CK; Yoo JY; Polito A; Quan S; Han JH
    Korean J Intern Med; 1992 Jan; 7(1):13-7. PubMed ID: 1282364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
    Shiffman ML; Hofmann CM; Thompson EB; Ferreira-Gonzalez A; Contos MJ; Koshy A; Luketic VA; Sanyal AJ; Mills AS; Garrett CT
    Hepatology; 1997 Sep; 26(3):780-5. PubMed ID: 9303513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
    Bell H; Hellum K; Harthug S; Maeland A; Ritland S; Myrvang B; von der Lippe B; Raknerud N; Skaug K; Gutigard BG; Skjaerven R; Prescott LE; Simmonds P
    Scand J Infect Dis; 1997; 29(1):17-22. PubMed ID: 9112292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.
    Reichard O; Glaumann H; Norkrans G; Wejstål R; Fryden A; Schvarcz R; Weiland O
    Liver; 1994 Aug; 14(4):169-74. PubMed ID: 7526108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.
    Sánchez-Tapias JM; Forns X; Ampurdanés S; Titó L; Planas R; Viver JM; Acero D; Torres M; Mas P; Morillas R; Forné M; Espinós J; Llovet JM; Costa J; Olmedo E; López-Labrador FX; Jiménez de Anta MT; Rodés J
    Gut; 1996 Apr; 38(4):603-9. PubMed ID: 8707096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C.
    Kakumu S; Aiyama T; Okumura A; Iwata K; Ishikawa T; Yoshioka K
    J Gastroenterol Hepatol; 1997 Jun; 12(6):468-72. PubMed ID: 9195406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon-alpha.
    Kanto T; Hayashi N; Takehara T; Hagiwara H; Mita E; Oshita M; Katayama K; Kasahara A; Fusamoto H; Kamada T
    J Med Virol; 1995 Jul; 46(3):230-7. PubMed ID: 7561795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis.
    Saracco G; Abate ML; Baldi M; Calvo PL; Manzini P; Brunetto MR; Oliveri F; Kuo G; Chien D; Houghton M
    Liver; 1994 Apr; 14(2):65-70. PubMed ID: 7515141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells.
    Kusaka S; Okusa T; Araki A; Fujiki K; Takashimizu I; Okayasu I; Yamamoto N; Sato C
    J Med Virol; 1995 Jul; 46(3):265-8. PubMed ID: 7561801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
    Magrin S; Craxi A; Fabiano C; Marino L; Fiorentino G; Lo Iacono O; Volpes R; Di Marco V; Almasio P; Vaccaro A; Urdea MS; Wilber JC; Bonura C; Gianguzza F; Capursi V; Filiberti S; Stuyver L; Pagliaro L
    J Hepatol; 1996 Nov; 25(5):583-90. PubMed ID: 8938531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon therapy in chronic hepatitis C virus infection.
    Weiland O
    FEMS Microbiol Rev; 1994 Jul; 14(3):279-88. PubMed ID: 8086199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
    Mizokami M; Orito E; Gibo Y; Suzuki K; Ohba K; Ohno T; Lau JY
    Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial.
    Kiso S; Kawata S; Tamura S; Imai Y; Inui Y; Nagase T; Maeda Y; Yamasaki E; Tsushima H; Igura T; Himeno S; Seki K; Matsuzawa Y
    J Gastroenterol; 1997 Feb; 32(1):56-62. PubMed ID: 9058296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis.
    Magrin S; Craxì A; Fabiano C; Fiorentino G; Marino L; Almasio P; Pinzello GB; Palazzo U; Vitale M; Maggio A
    J Med Virol; 1992 Nov; 38(3):200-6. PubMed ID: 1283753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.
    Lampertico P; Rumi M; Romeo R; Craxì A; Soffredini R; Biassoni D; Colombo M
    Hepatology; 1994 Jan; 19(1):19-22. PubMed ID: 7506225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year.
    Caporaso N; Suozzo R; Morisco F; D'Antonio M; Romano M; Coltorti M
    Ital J Gastroenterol; 1993; 25(9):482-6. PubMed ID: 8123895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.